Open-Label, Dose-Escalating, Phase I Study of TG4040 (MVA-HCV) in Treatment-naïve Patients Chronically Infected With Hepatitis C Virus (HCV Genotype 1).

Trial Profile

Open-Label, Dose-Escalating, Phase I Study of TG4040 (MVA-HCV) in Treatment-naïve Patients Chronically Infected With Hepatitis C Virus (HCV Genotype 1).

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2011

At a glance

  • Drugs TG 4040 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Aug 2011 Added purpose and treatment tables
    • 23 Aug 2011 Results published in the Nature Reviews Gastroenterology and Hepatology journal and the Gastroenterology journal, according to a Transgene media release.
    • 02 Sep 2010 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top